Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
NCT06925126 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-04-13
Summary
The goal of this observational study is to develop an exosome-based scoring model for post-treatment surveillance of recurrence in ovarian cancer. The main questions it aims to answer are:
1. Does this model have the potential for ovarian cancer recurrence monitoring?
2. Can this model demonstrate superior performance to CA125 for ovarian cancer recurrence monitoring?
Participants will :
1. Provide serial blood samples at predefined times
2. Undergo standardized imaging and clinical assessments during follow-up visits
Conditions
Interventions
- OTHER
-
Not applicable- observational study
This is an observational cohort study with no planned interventions. Participants will be followed over multiple time points to evaluate treatment outcomes based on the standard care process.
Sponsors & Collaborators
-
Fudan University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-01
- Primary Completion
- 2027-06-01
- Completion
- 2027-12-31
More Related Trials
-
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
NCT06315270 ·Status: NOT_YET_RECRUITING
-
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT05316129 ·Status: RECRUITING ·Phase: PHASE1
-
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
NCT06279104 ·Status: RECRUITING
-
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072 ·Status: RECRUITING ·Phase: NA
-
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917 ·Status: RECRUITING
-
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
NCT07171528 ·Status: RECRUITING ·Phase: PHASE2
-
Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence
NCT06237946 ·Status: NOT_YET_RECRUITING
-
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine
NCT02178670 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
NCT07120451 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
NCT06544460 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
NCT06846424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
NCT03738319 ·Status: UNKNOWN
-
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
NCT05976932 ·Status: UNKNOWN
-
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686 ·Status: RECRUITING ·Phase: NA
-
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961 ·Status: UNKNOWN
-
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
NCT07295132 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
NCT05607329 ·Status: RECRUITING ·Phase: NA
-
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT01652794 ·Status: COMPLETED ·Phase: PHASE1
-
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
NCT05704621 ·Status: RECRUITING ·Phase: PHASE2
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN
-
An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer
NCT06468254 ·Status: RECRUITING ·Phase: PHASE2
-
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
NCT06541171 ·Status: NOT_YET_RECRUITING
-
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122 ·Status: COMPLETED
-
Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer
NCT06553612 ·Status: RECRUITING ·Phase: NA
-
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
NCT06682572 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2